Guotou Health is a wholly-owned subsidiary of Guotou and serves as a platform dedicated to investment, operation, and management in the health and elderly care industry. It is committed to providing comprehensive and full-cycle solutions for health and elderly care for the Chinese population. Currently, Guotou Health has invested in and operates health and elderly care projects in Beijing, Shanghai, Guangzhou, Xiamen, Changzhou, and Guiyang. It has also completed project reserves in Guangzhou, Suzhou, Wuxi, Yancheng, Langfang, and other locations.

Baycrest Health Sciences is a global leader in elderly healthcare, research, innovation, education, and daily living, focusing on brain health and aging. As an academic health sciences center fully affiliated with the University of Toronto, Baycrest provides exemplary care experiences for elderly clients and offers extensive clinical training programs for students and trainees in the world's top cognitive neuroscience research institutions.

CNNC Medical Industry Management Co., Ltd. was established in November 2015 as a wholly state-owned company entrusted by China National Nuclear Corporation (CNNC) to invest and establish through China National Nuclear Corporation Baoyuan Asset Holdings Co., Ltd. CNNC is a super-large state-owned enterprise approved by the State Council. As a professional platform under the CNNC group engaged in medical and health industry investment and management, CNNC Medical is dedicated to hospital investment and operation management, health management, medical and elderly care integration, pharmaceutical operations, and the development of nuclear characteristic medicine. The company is headquartered in Suzhou, Jiangsu Province, under the name "China National Nuclear Corporation Hospital Management Center." Currently, CNNC Medical has five member hospitals, including the General Hospital of CNNC (Second Affiliated Hospital of Soochow University), the 416 Hospital of CNNC (Second Affiliated Hospital of Chengdu Medical College), the 417 Hospital of CNNC, the 419 Hospital of CNNC, and the Beijing Hospital of CNNC, with a total of nearly 3,500 beds. During the "13th Five-Year Plan" period, CNNC Medical will focus on the construction of central medical institutions, gradually improve regional layout, reduce operating costs, enhance operational efficiency through industrial integration of medical resources, and achieve rapid development in the company's core business areas. Looking ahead, CNNC Medical will adhere to the purpose of "developing nuclear power and serving society" of the CNNC group, adhere to the development positioning of "based on nuclear industry, expanding nuclear medicine, serving the whole society, and developing a healthy society," continuously improve quality, optimize services, deepen connotations, gradually develop into an influential large medical group in China, serve public health, fulfill the social responsibility of central enterprises, and make new contributions to the development of the national medical and health industry!

Founded in November 2013, Lioshine Technologies is a high-tech enterprise focused on high-quality innovative drug research and development in the two major fields of anti-tumor and nervous system. After years of development, Lioshine has a research and development team led by academicians and composed of numerous top-notch Ph.D. talents, as well as multiple national major invention patents. The company has established its own large-scale raw material planting base and has set up new drug research and development centers and pilot platforms in multiple locations across the country. It has now formed a complete and efficient drug research and development system covering drug discovery, design, synthesis, toxicology, pharmacology research, and application filing. Lioshine has also laid out the entire industry chain for production and sales.

Established in 2001, Beijing Paisen Pharmaceutical Technology Co., Ltd. is a specialized neurodiagnostic company that integrates basic research on neurodegenerative disease biomarkers, production and sales of diagnostic reagents, and provision of scientific research testing services. The company has an internationally advanced research and technical support team, equipped with state-of-the-art instruments and devices, and uses diagnostic reagents approved by the U.S. FDA and European IVDR for research services. The experimental processes are standardized, and the results are reported promptly and accurately. The company collaborates extensively with domestic and international universities and enterprises, achieving multiple innovative results in the diagnosis and treatment of Alzheimer's disease.